{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-010537","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.786738+00:00","generated_at":"2026-06-04T04:12:15.323522+00:00","sec_items":["2.06","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions","bullets":["Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.","Goodwill impairment of ~$123M ($98M Clinical Genomics, $25M Biopharm Dev) and intangible asset impairment of ~$148M ($114M and $34M).","Driven by restructuring (eliminated 17 positions), loss of Sema4 as customer, macro uncertainty, and higher discount rates.","Non-cash charge does not affect cash flows from operations; final amounts subject to change upon 10-K filing.","Management cites new strategies, downward revenue revisions, and elevated interest rates as key factors."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-010537","json":"https://secwatch.observer/filing/0001437749-24-010537.json","markdown":"https://secwatch.observer/filing/0001437749-24-010537.md","text":"https://secwatch.observer/filing/0001437749-24-010537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/0001437749-24-010537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/mlab20240401_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:12:15.323522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}